clinical trial · NCT07078955
A Dose Regimen Study of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
Dry Eye Disease (DED)Keratoconjunctivitis SiccaBRM421 Ophthalmic Solution, 0.03%Artificial TearBRM421 Ophthalmic Solution, 0.06%
brief summary
To evaluate the safety and efficacy of BRM421 Ophthalmic Solution compared to artificial tear for treatment of the signs and symptoms of dry eye disease (DED)
started
Dec 1, 2025
primary completion
Nov 1, 2026
completion
Mar 1, 2027
last updated
Oct 20, 2025
official title
A Phase 2, Multicenter, Randomized, Open-Labeled, Artificial Tear-Controlled, 6-Week Clinical Study to Assess the Dose Regimen, Safety and Efficacy of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol